congresses-banner

The content contained is subject

PublicationView

Poster
T-DXd
ASCO GI 2024 | January 18-20, 2024
Gastric Cancer
Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients with HER2+ and HER2-low gastric cancer (DESTINY-Gastric03)
Yelena Y. Janjigian
Poster
T-DXd
ASCO GI 2024 | January 18-20, 2024
Gastric Cancer
Real-world experience with trastuzumab deruxtecan among patients with gastric cancer: 4 month-interim analysis of an all-patient post-marketing surveillance study in Japan
Hisato Kawakami
Poster
T-DXd
ASCO GI 2024 | January 18-20, 2024
Gastric Cancer
Retrospective cohort study to evaluate the efficacy and safety of T-DXd in HER2-positive unresectable advanced or recurrent gastric or gastroesophageal junction cancer: EN-DEAVOR study
Koki Nakanishi

footer